The global fluorescent in situ hybridization probe market size was valued at USD 996.6 million in 2014 and is expected to witness the significant growth of around 7.0% over the forecast period. Increasing incidences of target diseases and demand for in-vitro diagnostics (IVD) for detection of these diseases are expected to boost the demand for FISH probes over the forecast period.
U.S.FISH probe market, by type of RNA, 2012-2022 (USD Million)
In addition, rising healthcare expenditure levels, awareness pertaining to the use of fluorescent in situ hybridization probe based assays and adoption of these techniques in molecular diagnostic studies are some factors attributing towards the growth of the FISH probe market over the forecast period.
The market on the basis of the type of RNA used is categorized into mRNA, miRNA and others. mRNA dominated the FISH probe market accounting for over 35.0% of the total revenue in 2014. This dominance is attributed to the increasing demand for molecular profiling for patients coupled with application in detection and validation of cytogenetic diseases.
Advancements in molecular pathology techniques enabling accurate disease prognosis and stratification for appropriate treatment are expected to further augment growth opportunities for this segment. The miRNA segment is expected to grow at a lucrative CAGR of over 7.0% owing to factors such as the increasing R&D for development of miRNA probes and extensive usage of miRNA in cancer detection
FISH probe dominated the technology segment at over USD 400.0 million in 2014, owing to the increasing adoption of in-vitro diagnostic testing coupled with an upsurge in demand for rapid and accurate assays for IVD testing. Flow-FISH, Q FISH and others such as multiplex and multicolor are the modifications in the regular probe.
Flow-FISH is expected to register significant growth owing to associated benefits such as approximate detection of telomere length in case of large population studies. CISH market is expected to register lucrative growth of over 7.5% over the forecast period.
FISH probe are commonly used in research studies, clinical procedures, and companion diagnostics. As of 2014, clinical usage of this technique held the largest market share of over 40.0% attributed for by wide applications in the detection of cancer, genetic disorders, infectious diseases, and others.
The specificity, sensitivity of FISH and the rapid speed of performing assays have made this technique a pivotal cytogenetic procedure that gives significant advances in both diagnosis and research of solid tumors and hematological malignancies. Increasing demand for molecular cytogenetics is further expected to fuel the clinical use industry segment over the forecast period.
Increasing incidence rate of cancer globally, coupled with demand for early and accurate prognostic tools attributed for the largest market share of over 40.0% in terms of revenue in 2014. These probes are most commonly used for cancer diagnostics and research for genetic diseases.
Breast cancer is the second largest cause of cancer death globally. According to the WHO statistics, in 2012, near about 1,676,727 cases of breast cancer were reported globally and this number is expected to grow over the forecast period. FISH evaluation gives an edge over other as it is useful in measuring over expression of HER-2 responsible for more effective personalized breast cancer management.
North America dominated the overall FISH probe market in 2014 at over 45.0% owing to the larger presence of target disease population base, sophisticated healthcare infrastructure, high patient awareness levels, extensive R&D pertaining to genetic disorders and healthcare expenditure. Furthermore, growing adoption of these assays pertinent to various genetic disorders is further expected to drive this regional industry growth.
Asia-Pacific is expected to witness a lucrative growth of CAGR 9.0% over the forecast period. The presence of high untapped opportunities, economic development,growing patient awareness levels and constantly improving healthcare infrastructure are some factors accounting for the rapid growth of Asia Pacific region. In addition, continuous R&D activity for cancer treatments is expected to fuel industry growth over the forecast period.
Key market participants include Mirus Bio LLC, Life Science Technologies, Perkin Elmer Inc., BioDot Inc., Horizon Diagnostics, Sigma Aldrich, Agilent Technologies, Abnova Corporation, Biosearch Technologies, Genemed Biotechnologies Inc., Affymetrix Panomics, F Hoffman La Roche AG, Oxford Gene Technology, Bio Care Medical LLC, EXIQON, and GSP Research Institute Co., Ltd.
The FISH probe market is oligopolistic in nature with companies such as Affymetrix, Abnova Corporation, Genemed Biotechnologies, Roche, and Life Science Technologies holding major share. Companies, in an attempt to gain a competitive edge, are adopting strategies such as specialized product development. For example, a disease-specific probe such as VYSIS ALK kit for lung cancer.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."